Hoffmann-la Roche Inc.

Siena Biotech S.p.a.

F. Hoffmann-la Roche Ag

Alexander V Mayweg

Bernd Kuhn

Peter Mohr

Johannes Aebi

Hans Peter Maerki

Benoit Hornsperger

Kurt E Amrein

Xuefei Tan

Yongfu Liu

Mingwei Zhou

Hans Hilpert

Thomas Johannes Woltering

Wolfgang Wostl

Wolfgang Guba

Harald Mauser

Emanuele Gabellieri

Mark Rogers-Evans

Henner Knust

Andrew William Thomas

Rainer Eugen Martin

Michelangelo Scalone

Robert Narquizian

Didier Rombach

Serena Maria Fantasia

Zhanguo Wang

Wenming Chen

Eoin Power

Matteo Andreini

Massimiliano Travagli

Benoît Hornsperger

Yonfu Liu

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, R, A, AAand n are as described herein, compositions including the compounds and methods of using the compounds. The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Bicyclic dihydroquinoline-2-one derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, A, Aand Aare as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Dihydroquinoline-2-one derivatives

The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4 oxazines as BACE1 and/or BACE2 inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, R, A and n are as described herein, compositions including the compounds and methods of using the compounds.

Phenyl-tetrahydroisoquinoline derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, A, A, A, A, Aand n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Bicyclic dihydroisoquinoline-1-one derivatives

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4-oxazepines as BACE1 and/or BACE2 inhibitors

Growing community of inventors

Shanghai, China

Alexander V Mayweg